XARACOLL is a late-stage bioresorbable collagen-matrix surgical implant being developed for postsurgical pain relief through the delivery of bupivacaine, a local anesthetic, at the surgical site.

XARACOLL has been studied in two Phase 3 trials in open inguinal hernia surgery.

The NDA for XARACOLL is under active review by the US FDA with a PDUFA user fee goal date of August 26,2020.